NKARTA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.79 USD | -0.89% |
|
-11.48% | +18.03% |
| Mar. 26 | Canaccord Genuity Adjusts Nkarta's Price Target to $16 From $15, Keeps Buy Rating | MT |
| Mar. 25 | HC Wainwright Adjusts Price Target on Nkarta to $22 From $20, Keeps Buy Rating | MT |
Chart calendar Nkarta, Inc.
11a1a9e6f73b4ac52bd1471fcf9.-ljrFf6gGRcyUqkskXuurtVggR2ZwjDoYwUUML3hSHg.gDGvJJTae3BQGegB3Rz-47oT4lP39UOYIWJRAsWoDSCfPJ1trvlBLnEzyg~96fadfbdf3981a2a9c5f101c5095f775
Upcoming events on Nkarta, Inc.
Past events on Nkarta, Inc.
| 2024-04-14 | CG Horizons in Oncology Virtual Conference - Panel |
| 2024-04-09 01:30 pm | Needham Healthcare Conference - Fireside Chat |
| 2024-03-26 02:00 pm | H.C. Wainwright Cell Therapy Virtual Conference - Fireside Chat |
| 2024-03-21 04:01 pm | Q4 2024 Earnings Release |
| 2024-03-11 12:00 pm | Leerink Partners Global Biopharma Conference - Fireside Chat |
| 2024-03-06 09:10 am | TD Cowen Health Care Conference - Panel |
| 2024-02-12 | Investor Meeting - Natural Killer Cells |
| 2023-11-28 12:30 pm | Evercore ISI HealthCONx Conference - Fireside Chat |
| 2023-11-14 10:55 am | Stifel Healthcare Conference - Fireside Chat |
| 2023-11-09 04:02 pm | Q3 2023 Earnings Release |
| 2023-10-17 08:00 am | Business Update Call |
| 2023-08-10 12:00 pm | Canaccord Genuity Growth Conference - Fireside Chat |
| 2023-08-10 07:01 am | Q2 2023 Earnings Release |
| 2023-06-27 08:00 am | NKX101 Clinical Trial Results Call |
| 2023-06-13 | Malignant Lymphoma International Conference - Abstract No : 389 |
| 2023-06-10 10:30 am | European Hematology Association Hybrid Congress - Presentation S261 |
| 2023-06-07 12:00 pm | Annual General Meeting |
| 2023-05-11 04:02 pm | Q1 2023 Earnings Release |
| 2023-04-20 03:00 pm | Canaccord Genuity Horizons in Oncology Virtual Conference - Panel |
| 2023-04-17 03:00 pm | Needham Healthcare Conference - Fireside Chat |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | -84,7 -88,0 3.78% | -116 -113 -2.94% | -126 -124 -1.44% | -114 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -51,5 -47,5 -8.53% | -86,4 -85,1 -1.51% | -119 -116 -2.85% | -132 -131 -0.77% | -120 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -91,4 -87,4 -4.56% | -86,1 -93,5 7.93% | -114 -113 -1.15% | -118 -117 -0.44% | -108 |
|
Net income Million USD | Released Forecast Spread | -21,1 | -91,4 -87,4 -4.56% | -86,1 -93,5 7.94% | -114 -113 -1.13% | -118 -119 1.56% | -108 |
|
EPS USD | Released Forecast Spread | -3,89 | -5,44 -15,6 65.02% | -2,62 -2,85 7.93% | -2,61 -2,57 -1.52% | -2,40 -2,43 1.03% | -2,10 |
| Announcement Date | 19/06/20 | 25/03/21 | 17/03/22 | 16/03/23 | 21/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -25,5 -24,2 -5.54% | -27,0 -27,0 0.08% | -29,6 -28,0 -5.7% | -34,3 -31,0 -10.5% | -33,5 -31,0 -8.19% | -36,0 -32,7 -10.05% | -27,3 -35,7 23.58% | -28,9 -27,0 -7.16% | -29,0 | -28,0 | -28,0 | -28,0 | -29,0 | |
|
EBIT Million USD | Released Forecast Spread | -22,9 -24,3 5.89% | -26,1 -24,1 -8.19% | -27,6 -27,3 -1.15% | -30,3 -29,3 -3.35% | -35,0 -31,7 -10.4% | -34,3 -34,4 0.12% | -36,9 -35,3 -4.55% | -29,3 -34,1 14.09% | -31,2 -30,2 -3.38% | -29,2 | -29,2 | -29,8 | -31,6 | -30,6 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -22,8 -24,3 5.94% | -26,0 -24,1 -7.82% | -26,9 -27,2 0.99% | -28,3 -29,0 2.11% | -32,6 -30,9 -5.44% | -30,8 -33,3 7.49% | -33,3 -32,8 -1.63% | -25,6 -30,9 16.91% | -27,8 -27,2 -1.9% | -26,3 | -26,0 | -26,7 | -28,7 | -29,9 |
|
Net income Million USD | Released Forecast Spread | -22,8 -24,3 5.94% | -26,0 -24,1 -7.82% | -26,9 -27,2 0.99% | -28,3 -29,1 2.67% | -32,6 -30,9 -5.44% | -30,8 -33,7 8.52% | -33,3 -33,1 -0.48% | -25,6 -32,2 20.41% | -27,8 -29,7 6.49% | -26,3 | -26,1 | -26,7 | -28,7 | -29,8 |
|
EPS USD | Released Forecast Spread | -0,69 -0,95 27.11% | -0,79 -0,72 -9.91% | -0,61 -0,59 -3.57% | -0,58 -0,61 5.54% | -0,67 -0,64 -5.35% | -0,63 -0,70 9.48% | -0,68 -0,68 0% | -0,52 -0,67 22.82% | -0,57 -0,60 5.45% | -0,56 | -0,52 | -0,52 | -0,52 | -0,55 |
| Announcement Date | 17/03/22 | 12/05/22 | 11/08/22 | 09/11/22 | 16/03/23 | 11/05/23 | 10/08/23 | 09/11/23 | 21/03/24 | - | - | - | - | - |
More events
Past sector events for Nkarta, Inc.
| 2024-04-17 | BEIJING KAWIN TECHNOLOGY SHARE-HOLDING CO., LTD.: Q1 2024 Earnings Release (Projected) |
| 2024-04-17 | JIANGSU YAHONG MEDITECH CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-12 | SINOCELLTECH GROUP LIMITED: Q4 2023 Earnings Release |
| 2024-04-10 07:00 am | NURIX THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-04-08 | MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-02 03:06 am | TAIMED BIOLOGICS INC.: March 2024 Sales and Revenue Release |
| 2024-03-31 | PEPTRON, INC.: Q4 2023 Earnings Release (Projected) |
| 2024-03-31 | BIONEER CORPORATION: Q4 2023 Earnings Release (Projected) |
| 2024-03-29 08:30 am | INNOCARE PHARMA LIMITED: Q4 2023 Earnings Release |
| 2024-03-28 | BIO-THERA SOLUTIONS, LTD.: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- NKTX Stock
- Calendar Nkarta, Inc.
